HUM Humana Inc.

UnitedHealth (UNH) stock trades at 22.5 times its past year's adjusted earnings, which are normalized net income with stock-based pay added back. That multiple leaves little room for error after three years of shrinking operating margins, sitting near the stock's 10-year median despite fundamentally weaker profitability. But the price looks different against the profit expected for fiscal 2026 and fiscal 2027. So what are UnitedHealth investors betting on.

What a time it’s been for Humana. In the past six months alone, the company’s stock price has increased by a massive 136%, reaching $391.06 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

UnitedHealth shareholders spent five years waiting for a stock that barely budged, yet something inside the company kept growing the whole time. Whether that something is enough to make UNH worth holding now depends on costs that management has not yet fully tamed.

Humana (HUM) moved sharply higher this week after Barclays shifted its rating on the insurer to Overweight from Equalweight, indicating that the shares could outperform sector peers. At around US$397.93, Humana’s recent 4.63% 1 day share price return and 3.21% 30 day share price return build on a strong year to date share price return of 50.46%. However, the 3 year total shareholder return has declined 15.34%, suggesting the latest upgrade is being read as a fresh shift in sentiment rather...

Shares of health insurance company Humana (NYSE:HUM) jumped 8% in the afternoon session after Barclays upgraded the stock from Equalweight to Overweight.

Healthcare stocks rose late Friday afternoon with the NYSE Healthcare Index increasing 0.3% and the

Investing.com -- Humana Inc. (NYSE:HUM) shares rose 6% Friday after Barclays upgraded the health insurer to overweight from equal-weight ahead of the upcoming Medicare Star ratings release.

Barclays just broke its silence on Humana with a conviction call that sent shares surging well past anything the broader health care sector is doing today, raising the question of whether this upgrade signals the start of something bigger or a rally built on a single opinion.

Barclays upgraded Humana stock to Overweight from Neutral and raised its price target to $515 from $407.

Twilio downgraded, Synopsys upgraded: Wall Street's top analyst calls

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.3%, and the actively tra

If you own CVS Health (CVS), the primary focus shifts from 2026 execution toward potential headwind variables heading into 2027. Management raised its 2026 earnings outlook on its fiscal Q2 2026 call in August. It also gave an early read on 2027, a quarter sooner than usual. One warning in that read came with no number. Over the past three months, the shares lost 15.2%, while the S&P 500 gained 5.0%. What is the 2027 problem CVS would not put a number on.

By Exec Edge Editorial Staff Health insurance premiums have climbed for years. Deductibles have climbed right along with them. Yet a growing number of American households are choosing neither, opting instead for a decades-old alternative, which is not health insurance, built around monthly contributions and community values. “People are clearly paying high premiums now,” Liberty […] The post Liberty HealthShare’s Dorsey Morrow Makes the Financial Case for Healthsharing on Becker’s Healthcare Pod

UnitedHealth Group (UNH) stock has risen about 40% since late March 2026, against close to 19% for the S&P 500. Read cold, that looks like a recovery nobody could have timed. It was not hidden. The company had said plainly, months before the shares turned, that it would give up members to rebuild margin.

UnitedHealth (UNH) has turned its profits around. Operating earnings rose 55% in the second quarter of 2026, and management raised its full-year adjusted earnings guide to $19.50 to $20 a share. Revenue, though, has nearly stopped growing. So the rest of the recovery rests on something the company only partly controls: the medical bills of the people it insures.

Humana is exiting plans and counting on hundreds of thousands of affected members to land back inside the company. Before you accept what arrives in that envelope this fall, there are four terms in the replacement plan that can quietly cost you thousands.

CI is expanding AI across care coordination and specialty pharmacy as it seeks to manage elevated healthcare costs and improve access.

CVS Health (CVS) keeps a little over a penny of profit from every dollar it takes in. A net margin of 1.2% reads like a verdict on the business. On $415.1 billion of revenue, one point of net margin is worth over $4 billion, and 1.2% is closer to a floor than a peak. Management has been working on it through 2026.

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.

CNC's profitability is recovering, but rising margins face a key test as Medicaid membership declines and eligibility reviews continue.

When the Federal Reserve lifts rates and signals they may stay elevated for years, the easy-growth playbook breaks. Cash flows today matter more than promises tomorrow, and investors start to care a lot about balance sheet strength, pricing power and dependable dividends. This article walks through three large cap quality defensive stocks that screen well under those rules and explains how the latest Fed move could affect each one. The three stocks below are a sample of what this quality...

Americans on Medicare Advantage plans may soon get a breakup letter in the mail: Your insurer is canceling your plan. Humana and other Advantage insurers are sending letters this fall to plan members about 2027 coverage. As insurers look to cut costs, some are discontinuing their Advantage plans.

UnitedHealth's repair job is going to plan almost everywhere. The exception is the cost of its commercial health plans, where medical costs are running modestly above the 11% the company had been expecting. Medicare costs are coming in below what it planned for 2026, and Medicaid cost trend is in line, though management expects Medicaid margins to stay pressured for 2026. That cost divergence is what a holder should watch.

Humana has staged a sharp rebound in 2024, and with the stock closing at US$407.02, the big question is whether that move still lines up with what the business earns. With the share price up 53.9% year to date, a lot of future expectations are already riding on Humana's earnings power. New research on integrated specialty pharmacy and the push toward lower drug costs may support more stable margins and cash flows, provided Humana can keep members engaged in these models. The analysts...

Humana listed Counterpart Health among the vendors for its provider-performance and quality programs.

The health care giant showered its owners with cash, yet the stock spent years in the slow lane. Here’s the accounting of what that trade-off actually delivered.

UnitedHealth (UNH) has spent the past year repairing margins rather than chasing growth. The shares rebounded well ahead of any actual margin recovery: up about 38% over the past six months, though down about 6% over the past three, and still behind the S&P 500 over the past twelve months, 12.2% for the stock against 18.6% for the index. What argues for owning them now shows up in cash running ahead of reported profit.

Elevance Health (ELV) has returned more than 40% over the past six months, though it is down 6.5% over the past three while the S&P 500 gained 3.4%. The next leg will not come from selling more insurance. It will come from keeping more of the premium it already collects.

UNH's TPG deal brings local support and investment to Florida WellMed clinics as Optum targets faster growth and stronger profitability.

BrightSpring Health Services' Specialty and Infusion sales rose 30%, backed by LDD growth, new launches and expansion into rare therapies.

On August 11, Humana Inc. (NYSE:HUM) announced that its Medicaid plan, Humana Healthy Horizons in Indiana, is collaborating with HealthStream, Inc. (NASDAQ:HSTM). The partnership expands access to workforce training for caregivers, aiming to recruit and retain talent in rural and underserved communities. While one provides healthcare coverage and the other builds the software to train […]

UnitedHealth (UNH) runs the best operating margin of the three managed care companies in its peer group, and the slowest revenue growth of the three. It also carries a significant valuation premium over its peer, Cigna, trading at more than double its earnings multiple.

UNH is investing nearly $1.5B in AI to expand Optum Insight's software offerings, boost efficiency and unlock new growth opportunities.

Humana has outperformed the broader Dow Jones index over the past year. Moreover, Wall Street analysts remain moderately optimistic about its prospects.

TPG just bought into the exact Optum clinics that derailed UnitedHealth's profits, and management is hours away from reaffirming guidance that could either validate the deal or reopen a wound investors hoped was healing.

Insurers spent the summer telling Wall Street exactly which Medicare Advantage plans are disappearing on December 31. Enrolled members get a letter in October, a closing enrollment window in December, and a rare legal protection most will never realize they have.

UNH's 39% six-month rally reflects improving medical costs, stronger earnings estimates and a sharper focus on profitable businesses.

“You get what you pay for” often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.

DaVita (DVA) is back in focus after two meaningful developments. The company expanded its value based care partnership with Humana for chronic kidney disease patients and agreed to a US$15 million settlement related to a prior data breach. Investors have been reacting to this mix of partnership news and legal resolution with a share price that is still up 58.64% year to date, despite a 30 day share price return of down 20.32%. The 3 year total shareholder return of 90.54% points to momentum...

Humana's non-renewal letters are already in the mail, and the deadline to act is closer than most affected members realize. Missing it by even one day changes what coverage options remain available and how much they cost.

UnitedHealth (UNH) stock has gained about 41% since early March, and at roughly $400 a share the market has already paid for a recovery. The easy reading is that the turnaround is finished. It is not. One half got better over those six months, the other got worse, and the price reflects the good half.

UNH is showing signs of recovery as medical costs improve, Optum gains momentum and 2026 earnings guidance rises.

The market has crowned this healthcare giant the winner of its group, but a look at the underlying business raises the question of whether the celebration started too soon.

A retirement community's top health provider quietly told the government it had been overbilling Medicare for years, then filed for bankruptcy before the consequences arrived. What happened next reshaped who owns the clinics, who absorbs the loss, and what federal prosecutors are targeting next.

Eagle Capital Management, an investment management company, released its second quarter 2026 investor letter. A copy of the letter can be downloaded here. In the quarter, Eagle Capital Management discussed how enthusiasm around AI capital spending has driven strong S&P 500 earnings growth while also increasing risks from elevated valuations, concentrated demand, and aggressive investment assumptions. […]

By endorsing Mark Cuban‘s proposals to make prescription drug pricing more transparent, Bill Ackman shifted the conversation from healthcare policy to something investors care about just as much: whether the traditional pharmacy benefit manager (PBM) model is facing a growing...

Daniel Chojnowski, JHHP’s current CFO, will provide stability so that the Baltimore-area insurer can recruit full-time for its next chief executive, the company said.

Humana (HUM) has drawn fresh attention after announcing that Shantanu Nundy, M.D., will become Chief Medical Officer on August 31, 2026, in a move that foregrounds technology, AI and clinical leadership. Humana’s appointment of a technology focused Chief Medical Officer comes as the stock trades at US$383.23. The share price return is up 5.32% over 30 days and 19.43% over 90 days, while the year-to-date share price return of 44.90% contrasts with a 3-year total shareholder return that has...

Consensus knocks a quarter off the health insurer's earnings multiple over two years, part of it measurement, and almost none of it from selling more coverage.

A non-renewal notice from Humana can feel like bad news, but buried inside federal Medicare rules is a protection that most long-time Advantage members have no idea they still qualify for.